“Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies”, J of Skin, vol. 4, no. 5, p. s55, Sep. 2020, doi: 10.25251/skin.4.supp.54.